2038 Stock Overview
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, develops, produces, and markets genetic engineering and related drugs in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Beijing SL Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.75 |
| 52 Week High | CN¥16.09 |
| 52 Week Low | CN¥7.05 |
| Beta | 0.35 |
| 1 Month Change | 2.10% |
| 3 Month Change | 3.67% |
| 1 Year Change | -7.11% |
| 3 Year Change | -26.47% |
| 5 Year Change | -43.08% |
| Change since IPO | -55.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2038 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 1.5% | 3.1% | 1.7% |
| 1Y | -7.1% | -14.2% | -9.5% |
Return vs Industry: 002038 exceeded the CN Biotechs industry which returned -14.2% over the past year.
Return vs Market: 002038 exceeded the CN Market which returned -9.5% over the past year.
Price Volatility
| 2038 volatility | |
|---|---|
| 2038 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in CN Market | 11.0% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 002038 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002038's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 856 | Mingbo Xu | www.slpharm.com.cn |
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, develops, produces, and markets genetic engineering and related drugs in the People’s Republic of China and internationally. The company’s finished formulations includes temozolomide; arsenic trioxide; lenalidomide capsules; docetaxel; paclitaxel; recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; liraglutide; insulin aspart 30; insulin aspart 50; insulin aspart; recombinant human follitropin(rh-fsh); ciclosporin; mycophenolate mofetil dispersible; voriconazole; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; rivaroxaban; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin; paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients.
Beijing SL Pharmaceutical Co., Ltd. Fundamentals Summary
| 2038 fundamental statistics | |
|---|---|
| Market cap | CN¥8.99b |
| Earnings (TTM) | CN¥284.90m |
| Revenue (TTM) | CN¥966.90m |
31.6x
P/E Ratio9.3x
P/S RatioIs 2038 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2038 income statement (TTM) | |
|---|---|
| Revenue | CN¥966.90m |
| Cost of Revenue | CN¥205.62m |
| Gross Profit | CN¥761.28m |
| Other Expenses | CN¥476.39m |
| Earnings | CN¥284.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 78.73% |
| Net Profit Margin | 29.47% |
| Debt/Equity Ratio | 0% |
How did 2038 perform over the long term?
See historical performance and comparison